Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryMar 02, 2016	Xencor to Present at Cowen and Company 36th Annual Health Care Conference MONROVIA, Calif. , March 2, 2016 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat , president	View HTML Xencor to Present at Cowen and Company 36th Annual Health Care Conference 15.7 KB
Toggle SummaryNov 04, 2015	Xencor to Present at Credit Suisse 24th Annual Healthcare Conference MONROVIA, Calif. , Nov. 4, 2015 /PRNewswire/ -- Xencor, Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat , president	View HTML Xencor to Present at Credit Suisse 24th Annual Healthcare Conference 15.4 KB
Toggle SummaryMay 02, 2018	Xencor to Present at Deutsche Bank 43rd Annual Health Care Conference MONROVIA, Calif. , May 2, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat , Ph.D.,	View HTML PDF Version
Toggle SummaryMay 22, 2014	Xencor to Present at Jefferies 2014 Global Healthcare Conference MONROVIA, Calif. , May 22, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat , Ph.D.,	View HTML Xencor to Present at Jefferies 2014 Global Healthcare Conference 12.6 KB
Toggle SummaryMay 26, 2015	Xencor to Present at Jefferies 2015 Healthcare Conference MONROVIA, Calif. , May 26, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat , President and	View HTML Xencor to Present at Jefferies 2015 Healthcare Conference 15.3 KB
Toggle SummaryMay 30, 2017	Xencor to Present at Jefferies 2017 Global Healthcare Conference MONROVIA, Calif. , May 30, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat, Ph.D.,	View HTML Xencor to Present at Jefferies 2017 Global Healthcare Conference 26.9 KB
Toggle SummaryFeb 09, 2017	Xencor to Present at Leerink Partners 6th Annual Global Healthcare Conference MONROVIA, Calif. , Feb. 9, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat , Ph.D.,	View HTML Xencor to Present at Leerink Partners 6th Annual Global Healthcare Conference 14 KB
Toggle SummarySep 24, 2015	Xencor to Present at Leerink Partners Inaugural Immuno-Oncology Roundtable MONROVIA, Calif. , Sept. 24, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat , president	View HTML Xencor to Present at Leerink Partners Inaugural Immuno-Oncology Roundtable 15.5 KB
Toggle SummaryMar 15, 2017	Xencor to Present at Oppenheimer 27th Annual Healthcare Conference MONROVIA, Calif. , March 15, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat , Ph.D.,	View HTML Xencor to Present at Oppenheimer 27th Annual Healthcare Conference 13.8 KB
Toggle SummaryNov 04, 2014	Xencor to Present at the 2014 Credit Suisse Annual Healthcare Conference MONROVIA, Calif. , Nov. 4, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat , Ph.D.,	View HTML Xencor to Present at the 2014 Credit Suisse Annual Healthcare Conference 12.7 KB

Tools

Press Releases